news
DNA methylation could determine liver disease progression
DNA methylation at specific genomic sites was found to correlate with non-fatty liver disease and could be used to diagnose severity.
List view / Grid view
Non-alcoholic steatohepatitis (NASH)
news
High-throughput method developed for single-cell metabolic profiling
Scientists have presented a new method for generating the metabolic profiles of cells which could answer questions on conditions such as cancer and liver disease.
article
Drug development in stem cell-derived liver organoid models
To ensure that new drugs are effective and have as little toxicity as possible, they first need to be tested in model systems before entering clinical trials. In this Q&A, Dr Takanori Takebe outlines his research into liver organoids derived from stem cells that can be used to test new…
news
New in vitro assay developed to test potential NASH drugs
An assay that combines 3D disease models and automated AI-based fibrosis quantification could accelerate NASH drug discovery.
news
Inhibiting the GLS1 enzyme could improve numerous age-associated disorders, finds study
In a new study, inhibitors of the GLS1 enzyme caused the death of senescent cells and relieved the symptoms of various age-related diseases in mice.
news
In vitro model could aid the development of fatty liver disease treatments
The patient-derived model of non-alcoholic fatty liver disease (NAFLD) accurately reproduced the complex human metabolic pathways involved in the development of the disease.
article
3D bioprinting COVID-19 lung models for drug development
Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.
article
Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
news
Organoids for the development of drugs and diagnostics for NASH
Organoids at different stages of non-alcoholic steatohepatitis (NASH) progression have been created to help in drug design and identification of diagnostic biomarkers.
news
PPARγ identified as liver fibrosis ‘off-switch’ in mice
A study identifying transcription factor differences in the hepatic stellate cells of mice with liver fibrosis named PPARγ as a potential target for the condition’s regression and scar resolution therapies.